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First results from five multidisciplinary diagnostic centre
(MDC) projects for non-specific but concerning symptoms,
possibly indicative of cancer
D. Chapman 1, V. Poirier 1, D. Vulkan 2, K. Fitzgerald 1, G. Rubin 3, W. Hamilton 4 and
S. W. Duffy 2 on behalf of the ACE MDC projects
BACKGROUND: Patients with non-specific symptoms often experience longer times to diagnosis and poorer clinical outcomes than
those with site-specific symptoms. This paper reports initial results from five multidisciplinary diagnostic centre (MDC) projects in
England, piloting rapid referral for patients with non-specific symptoms.
METHODS: The evaluation covered MDC activity from 1st December 2016 to 31st July 2018, with projects using a common dataset.
Logistical regression analyses were conducted, with a diagnosis of any cancer as the dependent variable. Exploratory analysis was
conducted on presenting symptoms and diagnoses of cancer, and on comparisons within these groupings.
RESULTS: In total, 2961 patients were referred into the MDCs and 241 cancers were diagnosed. The pathway detected cancers
across a broad range of tumour sites, including several rare and less common cancers. An association between patient age and
cancer was identified (p < 0.001). GP ‘clinical suspicion’ was identified as a strong predictor of cancer (p= 0.006), with a reduced
association with cancer observed in patients with higher numbers of GP consultation before referral (p= 0.008).
CONCLUSIONS: The MDC model diagnoses cancer in patients with non-specific symptoms, with a conversion rate of 8%,
demonstrating the diagnostic potential of a non-site-specific symptomatic referral pathway.
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BACKGROUND
Patients presenting with non-specific but concerning symptoms
(hereafter ‘non-specific symptoms’) account for a significant
proportion of cancer diagnoses in England.1 Some of these
symptoms, such as unexplained weight loss, non-specific abdom-
inal pain, fatigue and nausea/vomiting, have a low predictive
value for individual cancers.2–4 However, whilst the risk of specific
cancers may be low, the overall risk of harbouring cancer of any
type is higher,2,5 suggesting that swift investigation for patients
with non-specific symptoms is merited. In the absence of an
established pathway to ensure a timely and planned referral, these
patients have often experienced longer times to diagnosis than
those presenting with recognised high-risk symptoms indicative
of specific cancers.4,6,7
As non-specific symptoms can be caused by a range of
conditions, of which cancer is only one, identifying the appropriate
diagnostic test and referral route can be challenging. Consequently,
patients with non-specific symptoms more frequently have multiple
GP consultations before referral,6–8 potentially contributing to longer
intervals from presentation to diagnosis of cancer.6,7 Patients in this
cohort are also associated with higher rates of cancer diagnosis via
emergency presentation6,9 and of late-stage cancer diagnoses,6 both
of which contribute to poorer clinical outcomes10–12 and poorer
patient experience of care.13
The multidisciplinary diagnostic centre (MDC) concept aims to
improve outcomes for patients presenting with non-specific
symptoms by providing rapid access to a range of diagnostic tests
within a single diagnostic pathway, with a number of specialists
working together to speed up diagnosis for the patient.11 The MDC
concept was first trialled nationally in Denmark in 2012 as part of its
three-legged cancer strategy,14–16 with Diagnostic Centres estab-
lished alongside arrangements for the investigation of low-risk but
not no-risk symptoms (Yes/No Clinic), and an urgent referral
pathway for specific alarm symptoms. The Danish pathway
comprises a filter function conducted by the GP, which includes a
range of pre-specified diagnostic tests, followed by referral into the
Diagnostic Centre itself if serious symptoms persist without a
diagnosis being reached.14
The Accelerate Coordinate Evaluate (ACE) Programme17 of
interventions is aimed at improving the pathway to cancer
diagnosis, and thereby improving cancer outcomes, through the
provision of evidence-based information and support. Wave 2 of
the programme involved the establishment of a cluster of
five projects in England to examine and evaluate the concept of
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MDC-based pathways for patients presenting with non-specific
symptoms.
In this study, we evaluate the early outcomes for the ACE
Programme’s pilot MDC sites, in respect to patient characteristics,
cancer diagnoses and stage at diagnosis, and associations
between patient factors and diagnosis of cancer.
METHODS
Project structure
ACE MDC Programme activity was based within five projects in
England, with ten operational MDC pilot sites (Airedale, Greater
Manchester (×2), Leeds, London (×5) and Oxford). All projects focused
on the development of a pilot pathway for patients with non-specific
symptoms and, whilst projects configured their approaches to
reflect local healthcare systems and clinical priorities, a core set of
distinguishing features were evident across all pilot sites.18
As the programme was structured around a service evaluation of
pilot pathways, a level of heterogeneity was introduced amongst
the projects to test differing MDC approaches and to assess pathway
adaptability. However, regarding the clinical interpretation of the
patient’s presenting symptoms, all five projects adhered to two
fundamental principles for referral:
1. That the patient must be considered as being of clinical
concern, with non-specific symptoms potentially indicative
of cancer (or other serious disease) and
2. That their presenting symptoms are not sufficiently clear
to indicate an appropriate tumour-specific urgent referral
pathway.
As the MDC model focused on the diagnosis of any cancer
presenting with non-specific symptoms, and not being limited to
new cancer cases only, the presence of a previous cancer was
permitted, provided that the patient met the pathway’s two
governing principles for referral. Despite being considered a site-
specific symptom, painless jaundice was included as a referral
criterion in London MDC to reflect locally determined clinical
priorities.
Table 1 provides details of the date at which the intervention
was implemented, and the referral routes and the criteria for each
MDC project.
Research methods
A programme dataset was agreed across the projects to ensure a
robust evaluation. It included data items based on the English
cancer outcomes and services dataset,19 and additional project-
specific items focusing on secondary care presentation, diagnostic
process of cancers and other diseases. Data items were collected
locally from a combination of primary care referral forms and
secondary care data systems.
Data management arrangements varied between MDC projects;
a combination of local healthcare IT systems and stand-alone
systems were used, which impacted upon the availability of
certain data, for example, missing performance status and
comorbidity data items. The data items were captured in near
real time where possible either by automated data extraction or
entry by clinical staff. Some additional data required manual entry
at a later date.
All projects had a nominated data lead, and project data items
were submitted to programme evaluators on a quarterly basis,
Table 1. Initial MDC arrangements by individual project.
Airedale
Launch date 17th January 17
Referral criteria Persistent unexplained abdominal pain, persistent unexplained weight loss, non-specific but concerning symptoms with a high risk
of cancer, GP clinical suspicion and too unwell for 2-Week Wait referral
Referral route GP, A&E and Secondary Care Clinic
Greater Manchester
Launch date 3rd Mar 17 (Royal Oldham Hospital), 13th December 16 (Wythenshawe Hospital)
Referral criteria Non-specific abdominal pain, unexplained weight loss, severe unexplained fatigue, nausea/appetite loss, lymphadenopathy,
hepatomegaly, splenomegaly, bloating, GP clinical suspicion and non-iron- deficiency anaemia
Referral route GP
Leeds
Launch date 31st January 17
Referral criteria Appetite loss+ nausea (unexplained, 40 and over), weight loss (unexplained, 40 and over), abdominal pain without rectal bleeding
or weight loss (<3-month duration or recent change in character/severity, 50 and over), anaemia (non-iron deficiency, without
evidence of bleeding, 50 years and over), hypercalcaemia (unexplained and persisting <12 months), thrombocythemia (unexplained
and persisting <12 months and GP clinical suspicion and general condition (“poor” general condition)
Referral route GP, Acute Medicine
London
Launch date 1st May 17 (North Middlesex), 1st April 17 (UCLH), 1st December 16 (Queens—BHRUT), 1st January 18 (Royal Free Hospital) and 15th
September 2017 (Southend)
Referral criteria Broad range of abdominal symptoms with no clear referral pathway and where patients cannot wait for routine referral, including
new unexplained abdominal pain, unexplained weight loss, persistent nausea/appetite loss, GP clinical suspicion and painless
jaundice
Referral route GP
Oxford
Launch date 15th March 17
Referral criteria Severe unexplained fatigue, unexplained weight loss, persistent nausea or appetite loss, new atypical pain, unexplained laboratory
findings, no organ-specific symptoms, no symptoms fulfilling referral via the standard 2-week wait pathway, over 40 years old and
GP clinical suspicion (“gut feeling”)
Referral route GP
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where some recoding rules were applied to align the data for
analysis.
A list of thirteen symptoms (plus ‘other’) was included in the
agreed dataset. In subsequent analyses, these thirteen symptoms
are referred to together as ‘selected symptoms’. The range of
selected symptoms was developed with clinical guidance and
chosen to describe a general pattern of seriously unwell patients,
whose presentation is suggestive of cancer, but does not indicate
a specific diagnostic approach. In some instances, this includes
conditions and signs that are not strictly symptoms. In addition to
the thirteen ‘selected symptoms’, other symptoms were recorded
as part of open-ended data recording; these have been classified
as ‘non-selected’ symptoms.
Patients presented with non-specific symptoms in either
isolation or in varying combinations. Clinical judgement formed
part of the decision to refer, and all relevant factors were
considered as part of this process and captured on referral
templates where relevant. Eligible referral criteria were included
on MDC referral templates to aid consistency and quality, and to
clearly indicate patient symptoms as appropriate.
As indicated in Table 1, individual MDC hospital sites became
operational at different times and began contributing data at
different points during the evaluation period, from December
2016 to January 2018, with this evaluation covering MDC activity
up to 31st July 2018.
As projects have uniformly applied their selected referral
criteria, filter tests and diagnostic approaches to their own pilot
sites, data in this study are aggregated to a project and
programme level to provide greater scope for analysis. Although
measures were taken centrally to support data consistency and
completeness, a certain degree of variation in data interpretation
and formatting was created at MDC level. Additional variations in
the data completeness across the pilot sites were observed, often
due to manpower issues. Certain data items have approximately
one-third of data classified as ‘unknown’. Performance status20
was not recorded for 897 patients (30% of the total), and
comorbidity21 information was absent for 729 (25%). Performance
status and comorbidity, both of which had relevant data recorded
for four MDC projects only, were retained for the purpose of
describing the characteristics of the overall cohort.
The number of primary care consultations was missing for 1351
patients (46%), and symptom duration for 1012 (34%). In each
case, the extent of missing data varied by project site. Sensitivity
analyses have been conducted on primary care consultation
history and symptom duration to assess the likely impact of
missing data, as these data items have been included in logistic
regression analyses. Missing data are noted as unknown in the
tables, and records with missing data have been excluded from all
analyses relating to those fields (i.e. blanks have been omitted
from analyses).
Statistical analysis
Patients were deemed to have a cancer if their diagnostic
outcome was recorded as either “New cancer” or “Recurrence”.
A series of single-variable logistic regressions were carried out,
with diagnosis of any cancer as the dependent variable. Indepen-
dent variables considered were gender, age, number of primary care
consultations prior to referral (up to three, or three or more),
duration of symptoms (five categories), the presence of each of the
thirteen selected symptoms, including one general symptom (the
classification of ‘pain’ as a collective grouping of all pain-associated
symptoms, 85% of cases being abdominal pain) and the number of
selected symptoms reported.
To assess the likely impact of missing data relating to previous
primary care consultations and reported duration of symptoms,
two approaches were undertaken. The first approach was to omit
those sites where, for each variable considered, no data were
recorded for 20% or more of patients. The second approach was
to replace all missing values with, in turn, the highest or lowest
possible values of the variable, therefore creating a ‘best case’ and
‘worst case’ scenario for each variable. The results carried out
using these approaches did not provide strong evidence to
reconsider the conclusions reached. The results are presented in
Supplementary Information A.
Further logistic regression was carried out, taking multiple
independent variables into account at the same time. Statistically
significant (at the 0.05 level) factors identified in the single-variable
analyses (gender, age, fewer than 3 previous primary care
consultations, total number of selected symptoms, GP ‘clinical
suspicion’, nausea/appetite loss, fatigue and anaemia) were included
in multiple regression to assess possible confounding effects.
Multivariable analyses are presented as ‘adjusted’ rates alongside
the relevant ‘unadjusted’ single-variable rates.
RESULTS
There were 2961 patients referred to the pilot MDCs. Table 2
shows the demographic characteristics, comorbidity score and
primary care consultation history of the patients referred. Patients’
ages ranged from 17 to 97 years, with an average of 66.7 (SD 14.9).
Of the patients, 44% were male, 40% had some degree of physical
impairment (based on recorded performance status of 2064
completed patient records) and 27% had moderate or severe
comorbidities (based on 2232 completed patient records). Of
those with known primary care consultation history, 28% had 3 or
more previous consultations.
Table 3 shows the frequency of selected symptoms of referred
patients. The most common symptom was weight loss (66% of
those for whom symptoms were recorded) followed by GP ‘clinical
suspicion’ (36%) based on the GP’s clinical judgement regarding
overall suspicion of malignancy2 and pain (32%). In total, 61% of
patients presented with more than one of the thirteen selected
symptoms (decreasing to 57% when including non-selected
symptoms, but excluding GP ‘clinical suspicion’ and family
concern). Of those with symptom duration data, 55% reported a
symptom duration of 3 months or more.
Of the patients referred, 240 (8%) were diagnosed with cancer,
239 with a single cancer and one patient diagnosed with two
cancers (one urological and one lower GI). In the 16 cases where
cancer was classified as ‘recurrence’, all patients presented without
any recognised alarm symptoms. In addition to diagnoses of
cancer, over 50% of cases within the MDC were diagnosed with
non-cancer conditions; of those with a given diagnosis, 40% were
related to diseases of the digestive system.
Table 4 shows the sites of the cancers diagnosed. The
commonest were upper GI (including 25 cases of pancreatic
cancer) and lung, with 53 and 52 cancers diagnosed, respectively.
Table 5 shows the results of logistic regression for associations
of selected factors with a diagnosis of any cancer. When
considered in isolation, several factors displayed strong associa-
tions (p < 0.05) with a diagnosis of cancer. However, when
accounting for all significant individual variables at the same
time, strong associations were only identified between a cancer
diagnosis and increasing age (p < 0.001), and with GP ‘clinical
suspicion’ (p= 0.006) as a predictor of cancer. In addition, an
association was maintained between patients with more than
three GP consultations prior to referral (p= 0.008) and a reduced
likelihood of a cancer diagnosis.
The remaining factors, when included in multiple regression, no
longer recorded a statistically significant association with cancer
diagnosis, namely, gender (p= 0.172), nausea/appetite loss (p=
0.51), fatigue (p= 0.36), anaemia (p= 0.64) and the number of
symptoms reported (p= 0.53).
Table 6 shows the stage distribution of cancers diagnosed. For
all cancers, the majority were at stage III or IV. There were,
however, notable proportions at stage I and II for upper GI, lung
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and haematological cancers. For the haematological cancers,
however, stage was unavailable for more than 50% of the cancers.
DISCUSSION
The most important aspect of the study is that 8% of referrals
resulted in a cancer diagnosis, with 241 cancers diagnosed from a
referral cohort of 2961 patients. Thus, this study of activity within
the ACE pilot sites has shown that MDC-based pathways diagnose
cancer in patients presenting with non-specific symptoms.
Although most referrals do not result in a cancer diagnosis for
the patient, the reported conversion rate of 8% exceeds the
positive predictive value of 3% recommended for urgent definitive
investigation,2 and remains consistent with national guidance.
The MDCs diagnosed cancers across a broad range of tumour
sites, which is to be expected given the purpose of the pathway
and the non-specific symptoms of patients. Encouragingly, several
of these diagnoses were of rare and less common cancers,
Table 2. Characteristics of the patients referred to the MDC.
Total number of patients 2961
Sex N %
Male 1304 44.2
Female 1646 55.8
Unknown 11 N/A
Age group
Under 30 52 1.8
30–39 109 3.7
40–49 231 7.8
50–59 480 16.2
60–69 649 21.9
70–79 814 27.5
80–89 567 19.2
90–99 59 2
Mean (SD) 66.7 (14.9)
Median 69
Performance status
0 1239 60.0
1 462 22.4
2 232 11.2
3 113 5.5
4 18 0.9
Unknown 897 N/A
Comorbidity score
0 699 31.3
1 938 42.0
2 or 2/3 406 18.2
3 189 8.5
Unknown 729 N/A
Primary care consultations
None 114 7.1
1 539 33.5
2 501 31.1
3 221 13.7
4 91 5.7
5 50 3.1
More than 5 94 5.8
Unknown 1 351 N/A
Table 3. Nature, number and duration of symptoms in patients
referred to the MDC.
Reported symptoms As only
selected
symptom
With other
symptoms
All
occurrences
N % N % N %
Weight loss 579 20.3 1,295 45.4 1874 65.7
GP clinical suspicion 124 4.3 904 31.7 1028 36.1
Pain 248 8.7 678 23.8 926 32.5
Nausea/appetite loss 26 0.9 817 28.7 843 29.6
Fatigue 18 0.6 528 18.5 546 19.2
Anaemia 40 1.4 256 9 296 10.4
Change in bowel habit 9 0.3 119 4.2 128 4.5
General condition 6 0.2 97 3.4 103 3.6
Respiratory problem 5 0.2 67 2.4 72 2.5
Thrombocytosis 4 0.1 19 0.7 23 0.8
Jaundice 9 0.3 10 0.4 19 0.7
Hypercalcaemia 0 0 8 0.3 8 0.3
New-onset diabetes 0 0 3 0.1 3 0.1
Other symptom(s) (only) 43 1.5 N/A N/A 43 1.5
Unknown 110 N/A
Number of selected symptoms reported N %
None 43 1.5
1 1068 37.5
2 879 30.8
3 515 18.1
4 244 8.6
5 90 3.2
6 12 0.4
Overall number of symptoms per case**
1 or fewer 1234 43.3
2 or more 1617 56.7
Reported symptom duration
Less than 1 week 25 1.3
1–4 weeks 348 17.9
5–12 weeks 507 26.0
3–6 months 573 29.4
Over 6 months 496 25.5
Unknown 1012 N/A
**Including non-selected symptoms, excluding GP clinical suspicion and
patient/family concern.
Table 4. Anatomical sites of the 240 patients diagnosed with cancer.
Cancer site Number %
Upper GI 53 22
Lung 52 22
Haematological 31 13
Lower GI 30 13
Urological 30 13
Breast 15 6
Sarcoma 6 3
Lower GI and urological 1 0
Other 20 8
Unknown 2 1
First results from five multidisciplinary diagnostic centre (MDC). . .
D. Chapman et al.
4
reflecting the higher risk of harbouring cancer of any type
amongst this patient group.2,5
Patient age was found to be the most important factor
associated with a cancer diagnosis (p < 0.001) and, once age was
controlled for, the significance of other factors was reduced. A
significant relationship was also detected between a diagnosis of
cancer and GP ‘clinical suspicion’ (p= 0.006), and is consistent
with GP ‘clinical suspicion’ being a powerful predictor of cancer.22
The reduced association between a cancer diagnosis and patients
with more than three GP consultations prior to referral is also
Table 5. Logistic regression results for associations of selected factors with diagnosis of cancer.
Category—factor Cancer N (%) No cancer N (%) Single variable ‘unadjusted' Multivariable ‘adjusted’**
Odds ratio (95% CI) Significance Odds ratio (95% CI) Significance
Sex
Male 122 (9.4) 1 182 (90.6) 1.00 0.027 1.00 0.172
Female 117 (7.1) 1 529 (92.9) 0.74 (0.57–0.97) 0.77 (0.53–1.12)
Age
Per year of age N/A 1.04 (1.03–1.06) <0.001* 1.05 (1.03–1.07) <0.001*
Previous 1° care consultations
<= 3 122 (8.9) 1 253 (91.1) 1.00 0.002 1.00 0.008
> 3 6 (2.6) 229 (97.4) 0.27 (0.12–0.62) 0.32 (0.14–0.75)
Duration of symptoms
<1 week 2 (8.0) 23 (92.0) 1.00 0.038 – –
1–4 weeks 43 (12.4) 305 (87.6) 1.62 (0.37–7.12) –
5–12 weeks 44 (8.7) 463 (91.3) 1.09 (0.25–4.79) –
3–6 months 49 (8.6) 524 (91.4) 1.08 (0.25–4.70) –
>6 months 30 (6.0) 466 (94.0) 0.74 (0.17–3.29) –
Symptoms (selected)
Weight loss N: 76 (7.8) 901 (92.2) 1.05 (0.79–1.39) 0.76 – –
Y: 152 (8.1) 1 722 (91.9)
GP clinical suspicion N: 113 (6.2) 1 710 (93.8) 1.91 (1.45–2.50) <0.001 1.88 (1.20–2.94) 0.006
Y: 115 (11.2) 913 (88.8)
Pain N: 154 (8.0) 1 771 (92.0) 1.0 (0.75–1.33) 0.99 – –
Y: 74 (8.0) 852 (92)
Nausea/appetite loss N: 144 (7.2) 1 864 (92.8) 1.43 (1.08–1.90) 0.012 1.18 (0.72–1.95) 0.51
Y: 84 (10.0) 759 (90.0)
Fatigue N: 166 (7.2) 2 139 (92.8) 1.65 (1.21–2.25) 0.001 1.29 (0.75–2.20) 0.36
Y: 62 (11.4) 484 (88.6)
Anaemia N: 186 (7.3) 2 369 (92.7) 2.11 (1.47–3.02) <0.001 1.16 (0.63–2.13) 0.64
Y: 42 (14.2) 254 (85.8)
Change in bowel habit N: 219 (8.0) 2 504 (92.0) 0.86 (0.43–1.72) 0.68 – –
Y: 9 (7.0) 119 (93.0)
General condition N: 222 (8.1) 2526 (91.9) 0.70 (0.31–1.62) 0.41 – –
Y: 6 (5.8) 97 (94.2)
Respiratory problem N: 220 (7.9) 2 559 (92.1) 1.45 (0.69–3.07) 0.33 – –
Y: 8 (11.1) 64 (88.9)
Thrombocytosis N: 226 (8.0) 2602 (92.0) 1.10 (0.25–4.71) 0.9 – –
Y: 2 (8.7) 21 (91.3)
Jaundice N: 226 (8.0) 2606 (92.0) 1.36 (0.31–5.91) 0.69 – –
Y: 2 (10.5) 17 (89.5)
Hypercalcaemia N: 227 (8.0) 2616 (92.0) 1.65 (0.20–13.44) 0.64 – –
Y: 1 (12.5) 7 (87.5)
New onset of diabetes N: 228 (8.0) 2620 (92.0) N/A N/A – –
Y: 0 (–) 3 (100.0)
Number of selected symptoms
Per additional selected symptom N/A 1.34 (1.20–1.49) <0.001* 1.09 (0.83–1.43) 0.53*
*Trend test.
**Multivariable analyses on gender, age, fewer than 3 previous primary care consultations, total number of selected symptoms, GP clinical suspicion, nausea/
appetite loss, fatigue and anaemia (pseudo-R2= 0.0921).
Bold values in the table denote significant results, whereas italic values denote non-significant results.
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noteworthy, despite partial data completeness being observed at
a project level. Within the context of this study, it may be that
where they have a strong suspicion of cancer, GPs are more likely
to pursue available options such as the MDC to achieve earlier
referral for these patients. Consequently, many of the cases of
cancer in this study may have been suspected and referred by the
GP during the first few consultations. Analyses of a similar patient
cohort suggest that, without a rapid referral route such as the
MDC, cancer patients with non-specific symptoms often experi-
enced greater numbers of GP consultations before referral than
those with site-specific symptoms,6 thus highlighting the potential
for this new approach.
The study has provided information that may be useful in
describing this new referral cohort. Notable proportions of patient
referrals in four MDC projects reported poor performance and
comorbidity. A strong association between these factors and
increasing age obfuscates the nature and significance of these
characteristics,23,24 but is useful in illustrating the complexity of
diagnostic decision-making for this patient group.
Several presenting symptoms recorded increased odds of a
cancer diagnosis, most notably fatigue (OR 1.29 (0.75–2.20)),
nausea/appetite loss (OR 1.18 (0.72–1.95)) and anaemia (OR 1.16
(0.63–2.13)), whilst the risk of cancer also marginally increased per
additional symptom reported (OR 1.09 (0.83–1.43)), although none
of these were statistically significant. There was no clear effect of
the reported duration of symptoms overall, but data suggested an
increased association for a duration of 1–4 weeks, which then
declined for longer durations. However, this may be influenced by
challenges regarding objective and accurate symptom recall,3 and
a higher degree of precision in remembering the onset of more
recent symptoms.25 Collectively, such information may be helpful
in describing the type of patient and presenting a profile that may
benefit from urgent referral for non-specific symptoms.
There were relatively large proportions of subjects with stage IV
cancer. As several of the non-specific symptoms are systemic, they
are consistent with metastatic cancer. However, a substantial
proportion of early-stage lung, upper GI tract and haematological
cancers were diagnosed, indicating that such symptoms may also
provide an opportunity for timely diagnosis via a dedicated
referral pathway such as the MDC, for these cancers at least.
Furthermore, recent research indicates that a notable proportion
of some solid tumour cancers presenting with non-specific
symptoms were diagnosed at stages 1–3 (e.g. patients presenting
with abdominal pain (as single symptom: 67%, with other
symptom(s): 62%)), suggesting that early diagnosis for these
patients remains a possibility.26
It is possible that a number of cancers, including those at early
stage, were diagnosed ‘incidentally’, in that the symptom or
symptoms leading to referral were not caused by the cancer.
However, this does not necessarily mean that the symptoms were
not related to the cancer.27,28 They may, for example, have been of
chronic non-malignant diseases sharing risk factors with the
cancer.29,30
There are some notable limitations. Firstly, this is a cohort study
with no comparison group. This, in addition to the time-limited
nature of the evaluation, has limited the ability to make
judgements on the relative impact of the pathway being trialled
and its long-term effect on patient outcomes. Whilst MDCs have
provided an alternative rapid referral pathway for patients with
suspected serious illness, further evaluative assessment should
consider the balancing of benefit and harm regarding diagnostic
investigations amongst this cohort, and for whom a cancer
diagnosis occurs for a minority of patients. There was some
missing data associated with the evaluation arrangements and,
although measures were implemented to promote consistency
regarding data collection and reporting, a certain degree of
variation was evident due to localised data arrangements,
something that warrants detailed consideration regarding the
development of national data collection arrangements for similar
pathways. Therefore, the study is dependent on the quality and
completeness of the data collected. Finally, the study is based on a
relatively small sample size that should be considered when
assessing the pathway’s key findings.
The ACE Programme has evaluated MDC-based pathways for
the diagnosis of cancer amongst patients with non-specific
symptoms. Additional analyses on MDC diagnostic testing activity
and the results will elaborate on programme heterogeneity and
associated learning, and will contribute to existing descriptive
materials18 from the evaluation. Further analyses are also planned
regarding the diagnosis of non-cancer conditions. Programme
learning to date has informed the national development and
implementation of rapid diagnostic centres (RDC)31 in England as
part of the NHS Long Term Plan.32
It will be necessary to conduct further research on the longer-
term impact of MDC pathways on outcomes for patients
presenting with non-specific symptoms, and to build on existing
work to assess patient experience within the MDC.33 The
development of a viable comparator dataset will be essential to
support future evaluative assessments, including a full evaluation
of pathway health economics. These areas fall outside of the
specific focus of this paper, but will provide valuable additional
and complementary information in support of an emerging
evidence base.
CONCLUSIONS
This evaluation of MDC pilots in England has demonstrated the
potential of a dedicated referral pathway for patients presenting
Table 6. Stage distributions of cancers diagnosed.
Cancer type Stage 1 Stage 2 (incl. 1/2) Stage 3 Stage 4 (incl. 3/4) Known stage Unknown stage Total
N (%) N (%) N (%) N (%)
Upper GI 2 (4.3) 10 (21.3) 8 (17.0) 27 (57.4) 47 6 53
Lung 12 (25.5) 4 (8.5) 6 (12.8) 25 (53.2) 47 5 52
Lower GI 0 (–) 5 (17.2) 10 (34.5) 14 (48.3) 29 2 31
Urological 4 (16.7) 2 (8.3) 4 (16.7) 14 (58.3) 24 7 31
Haematological 3 (20) 2 (13.3) 6 (40) 4 (26.7) 15 16 31
Breast 4 (33.3) 0 (–) 0 (–) 8 (66.7) 12 3 15
Sarcoma 0 (–) 1 (16.7) 4 (66.7) 1 (16.7) 6 0 6
Other type 0 (–) 0 (–) 1 (7.7) 12 (92.3) 13 7 20
Unknown 0 0 0 0 0 2 2
Total 25 (13.0) 24 (12.4) 39 (20.2) 105 (54.4) 193 48 241
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with non-specific but concerning symptoms, and provides a
platform for the further development of the subject’s evidence
base. We found a strong association between a cancer diagnosis
and patient age, and have identified GP ‘clinical suspicion’ as a
strong predictor of cancer within this non-specific symptom
cohort. This study has demonstrated that a cancer referral
pathway for patients with non-specific but concerning symptoms
could be a valuable addition to the referral options for suspected
cancer, across a broad range of cancer sites.
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